NCT02428842 (BIO-RAIDs) is a NA clinical trial of Tumor biopsies in Cervical Cancer, sponsored by Institut Curie.

Who is sponsoring NCT02428842?

NCT02428842 is sponsored by Institut Curie.

What drugs are being tested in NCT02428842?

Interventions in NCT02428842: Tumor biopsies, Blood sampling.

What condition does NCT02428842 study?

NCT02428842 studies Cervical Cancer.

Is NCT02428842 still recruiting?

NCT02428842 is currently completed. Last updated 20 January 2023.

Last reviewed 2023-01-20 · How we verify

NCT02428842: BIO-RAIDs

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4)

Completed NA Last updated 20 January 2023

What this trial tests

NA trial testing Tumor biopsies in Cervical Cancer in 419 participants. Completed in 20 October 2020.

Timeline

24 October 2013

Primary endpoint
21 November 2018

20 October 2020

Quick facts

Lead sponsor	Institut Curie
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	419
Start date	24 October 2013
Primary completion	21 November 2018
Estimated completion	20 October 2020
Sites	24 locations across France, Netherlands, Serbia, Germany, Romania

Drugs / interventions tested

Tumor biopsies
Blood sampling — full drug profile →

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →

Sponsor

Institut Curie — full company profile →

Who can join

18 and older, female only, with Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective Multicentric European trial for Cervical cancer, not previously treated, with tumour biopsies, and blood collection for molecular analysis at predetermined time points.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer.
Jeannot E, Latouche A, Bonneau C, Calméjane MA, et al · · 2021 · cited 88× · PMID 34210686 · DOI 10.1158/1078-0432.ccr-21-0625
Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site.
Kamal M, Lameiras S, Deloger M, Morel A, et al · · 2021 · cited 75× · PMID 33191407 · DOI 10.1038/s41416-020-01153-4
Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.
Scholl S, Popovic M, de la Rochefordiere A, Girard E, et al · · 2019 · cited 35× · PMID 30952619 · DOI 10.1016/j.ebiom.2019.03.069
From prospective biobanking to precision medicine: BIO-RAIDs - an EU study protocol in cervical cancer.
Ngo C, Samuels S, Bagrintseva K, Slocker A, et al · · 2015 · cited 13× · PMID 26531748 · DOI 10.1186/s12885-015-1801-0
Genetic markers and phosphoprotein forms of beta-catenin pβ-Cat552 and pβ-Cat675 are prognostic biomarkers of cervical cancer.
Scholl SM, Beal J, de Koning L, Girard E, et al · · 2020 · cited 9× · PMID 33096476 · DOI 10.1016/j.ebiom.2020.103049
RAIDS atlas of significant genetic and protein biomarkers in cervical cancer.
Scholl S, Roufai DB, Chérif LL, Kamal M. · · 2023 · cited 2× · PMID 37668079 · DOI 10.3802/jgo.2023.34.e74
Methylation, Gene Expression, and Risk Genotypes at the TERT-CLPTM1L Locus in Cervical Cancer.
Ramachandran D, Mao Q, Liao D, Kamal M, et al · · 2025 · cited 1× · PMID 39352309 · DOI 10.1002/mc.23822
Systematic assessment of tumor necrosis at baseline in cervical cancer - An independent factor associated with poor outcome.
Chouchane-Mlik O, Oniga A, Latouche A, Halladjian M, et al · · 2024 · cited 1× · PMID 38135059 · DOI 10.1016/j.humpath.2023.12.003

Verify or expand the search:

Other trials of Tumor biopsies

Trials testing the same drug.

NCT03946358 — Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) · Phase 2 · completed
NCT03388632 — Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory · Phase 1 · completed

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other Institut Curie trials

Trials by the same sponsor.

NCT07357948 — Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy · NA · not yet recruiting
NCT07491380 — Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TD · NA · not yet recruiting
NCT07193394 — Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer · Phase 2 · recruiting
NCT06225505 — Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) · NA · recruiting
NCT06659705 — Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI) · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02428842 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Curie
Last refreshed: 20 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02428842.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing